Datavant Showcases Lifecycle Evidence Strategy and RWE Capabilities at ISPOR Annual

A LinkedIn post from Datavant highlights the company’s planned participation in the ISPOR Annual meeting, where it will host a theater session on operationalizing lifecycle evidence for treatment utilization and outcomes insights. The session, scheduled for Tuesday, May 19, is described as using a real-world case to illustrate how evidence strategy, scalable data infrastructure, and governance can enable more timely, informed decisions.

The post notes that the panel will cover designing studies for critical post-launch questions, selecting meaningful endpoints and data sources, and aligning evidence generation with market access, positioning, and performance monitoring goals. This emphasis suggests Datavant is positioning its platform as integral to end-to-end evidence generation across the product lifecycle, which may support deeper engagement with life sciences clients focused on HEOR and real-world evidence.

The company’s presence at booth No. 617 and the invitation to “continue the conversation” indicate an effort to convert conference visibility into commercial discussions around its data connectivity and infrastructure offerings. For investors, this focus on HEOR and RWE use cases could imply an ongoing push to capture demand from pharmaceutical and biotech customers seeking robust post-launch analytics and health data solutions.

If the session and booth activity succeed in demonstrating tangible outcomes from Datavant-enabled evidence strategies, the company could strengthen its competitive standing in the health data and life sciences analytics ecosystem. Increased recognition at a specialized industry forum like ISPOR may also support pipeline development and longer-term revenue opportunities tied to real-world data, evidence generation services, and associated technology deployments.